| ICD-9-CM diagnosis codes | Description |
|---|---|
| Alcohol | |
| 304.80–304.83 | Combinations excluding opioids |
| 304.90–304.93 | Unspecified drug dependence |
| 305.90–305.93 | Other, mixed or unspecified drug abuse |
Other, mixed, or unspecified drug abuse, unspecified Short description: Drug abuse NEC-unspec. ICD-9-CM 305.90 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 305.90 should only be used for claims with a date of service on or before September 30, 2015.
Nondependent antidepressant type drug abuse, episodic; Polysubstance abuse; ICD-10-CM F19.10 is grouped within Diagnostic Related Group(s) (MS-DRG v 38.0): 894 Alcohol, drug abuse or dependence, left ama; 895 Alcohol, drug abuse or dependence with rehabilitation therapy; 896 Alcohol, drug abuse or dependence without rehabilitation therapy with mcc
We used codes from ICD-9-CM to identify chronic health conditions, acute infections, and in-hospital procedures. The ICD-9-CM codes do not distinguish between IVDU and non-intravenous drug use; thus, we adapted an algorithm developed by Tookes and colleagues to identify patients with recent opioid-IVDU [6].
Z79.0 Long term (current) use of anticoagulants and... Z79.02 Long term (current) use of antithrombotics/an... Z79.1 Long term (current) use of non-steroidal anti...
ICD-10-CM Diagnosis Code Z79 Z79.
ICD-9-CM codes: 291 (alcoholic psychoses), 292 (drug psychoses), 303 (alcohol dependence), 304 (drug dependence), or 305 (nondependent abuse of drugs); OR.
Substance use disorders and ICD-10-CM codingMental and Behavioral Disorders due to...Code1...use of opioidsF11...use of cannabisF12...use of sedatives, hypnotics, anxiolyticsF13...use of cocaineF146 more rows•Sep 10, 2015
Other psychoactive substance abuse, uncomplicated F19. 10 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM F19. 10 became effective on October 1, 2021.
Overview. A substance use disorder (SUD) is a mental disorder that affects a person's brain and behavior, leading to a person's inability to control their use of substances such as legal or illegal drugs, alcohol, or medications.
T50.911APoisoning by multiple unspecified drugs, medicaments and biological substances, accidental (unintentional), initial encounter. T50. 911A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
F11.1 Opioid abuse.F11.12 Opioid abuse with intoxication.F11.15 Opioid abuse with opioid-induced psychotic disorder.F11.18 Opioid abuse with other opioid-induced disorder.F11.2 Opioid dependence.F11.22 Opioid dependence with intoxication.F11.25 Opioid dependence with opioid-induced psychotic disorder.More items...•
20 Alcohol dependence, uncomplicated.
The ICD-10 code Z86. 4 applies to cases where there is "a personal history of psychoactive substance abuse" (drugs or alcohol or tobacco) but specifically excludes current dependence (F10 - F19 codes with the fourth digit of 2).
Personal history of drug therapy ICD-10-CM Z92. 29 is grouped within Diagnostic Related Group(s) (MS-DRG v39.0):
The Current Procedural Terminology (CPT) codebook contains the following information and direction for the Chemotherapy and Other Highly Complex Drug or Highly Complex Biological Agent Administration CPT® codes: “Chemotherapy Administration codes 96401-96549 apply to parenteral administration of non-radionuclide anti-neoplastic drugs; and also to anti-neoplastic agents provided for treatment of non-cancer diagnoses (e.g. cyclophosphamide for auto-immune conditions) or to substances such as certain monoclonal antibody agents, and other biologic response modifiers. The highly complex infusion of chemotherapy or other drug or biologic agents requires physician or other qualified health care professional work and/or clinical staff monitoring well beyond that of therapeutic drug agents (96360-96379) because the incidence of severe adverse patient reactions are typically greater. These services can be provided by any physician or other qualified health care professional. Chemotherapy services are typically highly complex and require direct supervision for any or all purposes of patient assessment, provision of consent, safety oversight, and intraservice supervision of staff. Typically, such chemotherapy services require advanced practice training and competency for staff who provide these services; special considerations for preparation, dosage, or disposal; and commonly, these services entail significant patient risk and frequent monitoring. Examples are frequent changes in the infusion rate, prolonged presence of the nurse administering the solution for patient monitoring and infusion adjustments, and frequent conferring with the physician or other qualified health care professional about these issues. When performed to facilitate the infusion of injection, preparation of chemotherapy agent (s), highly complex agent (s), or other highly complex drugs is included and is not reported separately. To report infusions that do not require this level of complexity, see 96360-96379. Codes 96401-96402, 96409-96425, 96521-96523 are not intended to be reported by the individual physician or other qualified health care professional in the facility setting.”
The subcutaneous or intravenous formulation of octreotide acetate is billed using HCPCS code J2354 with the JA (intravenous) or JB (subcutaneous) modifier.
J3358: Effective September 23, 2016, IV ustekinumab (Stelara®) should be billed with HCPCS J3590 (OPPS: C9399 for dates of service (DOS) before 04/01/2017; C9487 for DOS from 04/01/2017 to 06/30/17, Q9989 for DOS from 07/01/2017-12/31/17 and J3358 for DOS 01/01/2018 and after) for the initial IV dose of Stelara® when used for Crohn’s disease and Ulcerative Colitis and each subsequent subcutaneous dose must be billed with J3357. This IV formulation is now FDA approved for Crohn’s disease and Ulcerative Colitis. On and after July 31, 2017, both the drug and administration should be billed on the same claim with no other drugs or administration to prevent inappropriate claim rejection.
A situation in which the JW modifier is not permitted is when the actual dose of the drug or biological administered is less than the billing unit. For example, one billing unit for a drug is equal to 10mg of the drug in a single use vial. A 7mg dose is administered to a patient while 3mg of the remaining drug is discarded. The 7mg dose is billed using one billing unit that represents 10mg on a single line item. The single line item of 1 unit would be processed for payment of the total 10mg of drug administered and discarded. Billing another unit on a separate line item with the JW modifier for the discarded 3mg of drug is not permitted because it would result in overpayment. Therefore, when the billing unit is equal to or greater than the total actual dose and the amount discarded , the use of the JW modifier is not permitted.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.
Medicare has determined under Section 1861 (t) that these drugs may be paid when they are administered incident to a physician’s service and determined to be medically reasonable and necessary. Such determination of reasonable and necessary is currently left to the discretion of the Medicare Administrative Contractors (MACs). The documentation in the patient’s medical record must support the drugs as being medically reasonable and necessary.
Medicare will reject as unprocessable claims for NOC drugs and biologicals if any of the information above is missing, or if the NOC code is billed with more than one unit of service. (Note: The remittance notice will include remark code M123, "Missing/incomplete/invalid name, strength, or dosage of the drug furnished," even if the rejection is due to the number of units billed.)
patient presents with complaints of abdominal pain. An IV is started at KVO as a precautionary measure. Diagnostics are completed and the physician orders an IV antibiotic to be infused over 30 minutes.The primary service is:
patient arrives with gastroenteritis, nausea and vomiting. IV hydration is begun at 100 mls/hr at 1300 hours. Patient receives one IV push med and IV is continued until patient is discharged at 1435.